WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a therapeutically active agent and a pharmaceutically acceptable carrier, wherein:

(i) the therapeutically active agent reduces neuronal nitric oxide synthase (nNOS) activity selectively or preferentially in nervous tissue of a subject; and

(ii) the pharmaceutically acceptable carrier comprises at least one of a lipid, a surfactant, and a water-miscible organic solvent in an aqueous solution.

2. The pharmaceutical composition of claim 1, wherein the nervous tissue is central nervous system (CNS) tissue.

3. The pharmaceutical composition of claim 1, wherein the therapeutically active agent is an nNOS inhibitor.

4. The pharmaceutical composition of claim 3, wherein the nNOS inhibitor is one of 7-nitroindazole (7-NI), 3-bromo-7-nitroindazole (7-NI-Br), L-N^{ω}-propyl-L-arginine (N-PLA), N-PLA hydrochloride, N^5-(1-Imino-3-butenyl)-L-ornithine (vinyl-L-NIO), ARL 17477 dihydrochloride, JI-8, S-methyl-L-thiocitrulline, L-N^G-methyl-L-arginine (L-NMMA), L-N^G-nitroarginine (L-NNA), L-N^G-nitroarginine methyl ester (L-NAME), N^5-(1-iminobutyl)-L-ornithine (ethyl-L-NIO), N^5-(1-iminoethyl)-L-ornithine (L-NIO) dihydrochloride, L-thiocitrulline, methylene blue, S-methylisothiourea sulfate, 1400W dihydrochloride, 2,4-diamino-6-hydroxypyrimidine, 2-iminopiperidine hydrochloride, IC 87201, and any analog thereof.

5. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is one of saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, water, a cross-linked polyacrylic acid polymer, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.

6. The pharmaceutical composition of claim 1, wherein the lipid is one of a fatty acid, a fatty alcohol, a triglyceride, a hydrogenated vegetable oil, miglitol, a vegetable oil, and a wax.

7. The pharmaceutical composition of claim 1, wherein the surfactant is one of a polysorbate, a sorbitan ester, a PEG-lipid, and a PEG-hydrogenated castor oil.

8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated as a tablet, a capsule, a syrup, a solution, a spray, an aerosol, or a dispersion.

9. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for the treatment of a condition associated with elevated neuronal nitric oxide synthase (nNOS) activity.

10. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for the treatment of autism spectrum disorder (ASD).

11. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for the treatment of attention deficit hyperactivity disorder (ADHD) or attention deficit disorder (ADD).

12. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for the treatment of a condition selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, schizophrenia, addiction, amyotrophic lateral sclerosis (ALS), epilepsy, bipolar disease and migraine.

13. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for the treatment of a cancer of a neural origin or a neuroectodermal origin.

14. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for the treatment of a condition selected from the group consisting of neuroblastoma, glioma, ganglioglioma, central neurocytoma, ganglioneuroblastoma, medulloblastoma and a primitive neuroectodermal tumor (PNET).

15. The use of claims 9 -14, wherein the medicament is adapted for administration via a route selected from the group consisting of rectal, transmucosal, intestinal, parenteral, intramuscular, subcutaneous, intradermal, intramedullary, intrathecal, direct intraventricular, intravenous,

intraperitoneal, intranasal, intraocular, inhalation, insufflation, topical, cutaneous, transdermal and intra-arterial.

16. A pharmaceutical composition comprising an active agent which reduces neuronal nitric oxide synthase (nNOS) activity for use in treating autism spectrum disorder (ASD).

17. The pharmaceutical composition for use of claim 16, wherein the active agent is one of 7-nitroindazole (7-NI), 3-bromo-7-nitroindazole (7-NI-Br), L-N^{ω}-propyl-L-arginine (N-PLA), N-PLA hydrochloride, N^5-(1-Imino-3-butenyl)-L-ornithine (vinyl-L-NIO), ARL 17477 dihydrochloride, JI-8, S-methyl-L-thiocitrulline, L-N^G-methyl-L-arginine (L-NMMA), L-N^G-nitroarginine (L-NNA), L-N^G-nitroarginine methyl ester (L-NAME), N^5-(1-iminobutyl)-L-ornithine (ethyl-L-NIO), N^5-(1-iminoethyl)-L-ornithine (L-NIO) dihydrochloride, L-thiocitrulline, methylene blue, S-methylisothiourea sulfate, 1400W dihydrochloride, 2,4-diamino-6-hydroxypyrimidine, 2-iminopiperidine hydrochloride, IC 87201, and any analog thereof.

18. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of autism spectrum disorder (ASD) in a subject in need thereof, wherein the pharmaceutical composition comprises an active agent which reduces neuronal nitric oxide synthase (nNOS) activity.

19. The use of claim 18, wherein the active agent is one of 7-nitroindazole (7-NI), 3-bromo-7-nitroindazole (7-NI-Br), L-N^{ω}-propyl-L-arginine (N-PLA), N-PLA hydrochloride, N^5-(1-Imino-3-butenyl)-L-ornithine (vinyl-L-NIO), ARL 17477 dihydrochloride, JI-8, S-methyl-L-thiocitrulline, L-N^G-methyl-L-arginine (L-NMMA), L-N^G-nitroarginine (L-NNA), L-N^G-nitroarginine methyl ester (L-NAME), N^5-(1-iminobutyl)-L-ornithine (ethyl-L-NIO), N^5-(1-iminoethyl)-L-ornithine (L-NIO) dihydrochloride, L-thiocitrulline, methylene blue, S-methylisothiourea sulfate, 1400W dihydrochloride, 2,4-diamino-6-hydroxypyrimidine, 2-iminopiperidine hydrochloride, IC 87201, and any analog thereof.

20. A pharmaceutical composition comprising an active agent which reduces neuronal nitric oxide synthase (nNOS) activity for use in treating neuroblastoma.

21. The pharmaceutical composition for use of claim 20, wherein the active agent is one of 7-nitroindazole (7-NI), 3-bromo-7-nitroindazole (7-NI-Br), L-N^{ω}-propyl-L-arginine (N-PLA), N-

PLA hydrochloride, N^5-(1-Imino-3-butenyl)-L-ornithine (vinyl-L-NIO), ARL 17477 dihydrochloride, JI-8, S-methyl-L-thiocitrulline, L-N^G-methyl-L-arginine (L-NMMA), L-N^G-nitroarginine (L-NNA), L-N^G-nitroarginine methyl ester (L-NAME), N^5-(1-iminobutyl)-L-ornithine (ethyl-L-NIO), N^5-(1-iminoethyl)-L-ornithine (L-NIO) dihydrochloride, L-thiocitrulline, methylene blue, S-methylisothiourea sulfate, 1400W dihydrochloride, 2,4-diamino-6-hydroxypyrimidine, 2-iminopiperidine hydrochloride, IC 87201, and any analog thereof.

22. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of neuroblastoma in a subject in need thereof, wherein the pharmaceutical composition comprises an active agent which reduces neuronal nitric oxide synthase (nNOS) activity.

23. The use of claim 22, wherein the active agent is one of 7-nitroindazole (7-NI), 3-bromo-7-nitroindazole (7-NI-Br), L-N^{ω}-propyl-L-arginine (N-PLA), N-PLA hydrochloride, N^5-(1-Imino-3-butenyl)-L-ornithine (vinyl-L-NIO), ARL 17477 dihydrochloride, JI-8, S-methyl-L-thiocitrulline, L-N^G-methyl-L-arginine (L-NMMA), L-N^G-nitroarginine (L-NNA), L-N^G-nitroarginine methyl ester (L-NAME), N^5-(1-iminobutyl)-L-ornithine (ethyl-L-NIO), N^5-(1-iminoethyl)-L-ornithine (L-NIO) dihydrochloride, L-thiocitrulline, methylene blue, S-methylisothiourea sulfate, 1400W dihydrochloride, 2,4-diamino-6-hydroxypyrimidine, 2-iminopiperidine hydrochloride, IC 87201, and any analog thereof.